Active Nanoplatform with High Drug Loading Capacity for the Diagnosis and Treatment of Cancer

Abstract

Researchers at the University of California, Davis have developed an active nanoplatform (F/HAPIN) for cancer diagnosis and therapy.

Full Description

Nanoscaled drug delivery systems (NDDSs) are engineered by nanotechnologies for targeted delivery and controlled release of combinations of active pharmaceutical ingredients (APIs). The application of NDDSs in cancer improves the solubility of APIs, protects APIs from degradation without inducing side effects along the healthy organs. Nevertheless, current NDDSs suffer from low drug loading capacity.

Researchers at the University of California, Davis have developed a self-indicating combination of full/ high active pharmaceutical ingredients (API) loaded nanoplatform (F/HAPIN) for cancer diagnosis and therapy. The platform allows for nearly 100% combination drug loading with highly customizable drug delivery. Additionally, the platform has the capability to be both carrier-free and self-delivered while having controllable combination drug release. The use of the highly controllable platform with chemotherapeutic agents and photosensitizers achieves synergistic, precise and more efficient tumor ablation and lowers the risk of tumor recurrence in cancer.

Applications

• Cancer diagnosis and therapy
• Photodynamic diagnosis of tumors
• Photoacoustic tomography for lymphatic mapping and tumor detection
• PET imaging and radiotherapy
• MRI imaging
• Sonodynamic therapy

Features/Benefits

• Near 100% drug loading capacity
• Carrier-free and self-delivered
• Easily fabricated with simple chemical synthesis
• Synergistic effect
• Controllable drug release
• Self-indicating feature in vitro and in vivo dispositions fluorescently
• Structure-dependent fluorescence quenching

Patent Status